Genentech Pays Orionis US$47 M Upfront for Molecular Glue Medicines

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)

Published: 7 Oct-2023

DOI: 10.3833/pdr.v2023.i10.2806     ISSN: 1756-7874

Section: Licensing



Investing further into molecular glue degraders, Genentech has signed a multi-year collaboration with Orionis Biosciences to develop small molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details